Sai Parenteral's Ltd IPO

The company's Manufacturing Facilities are concentrated in Hyderabad, Telangana and Ongole, Andhra Pradesh. The company is exposed to risks originating from slowdown or shutdown, economic, regulatory, political and other changes in this region, including natural disasters, which could adversely affect its business, results of operations and financial condition.

Out of its diversified product portfolio, approximately 44.78%, 47.64% and 92.03% during the Fiscals 2025, 2024 and 2023, respectively of the company's Net Revenue from Operations was derived from the sale of injectables. Any reduction in demand for these products may adversely affect its business, financial condition, results of operations and cash flows.

The company's Manufacturing Facilities are subject to periodic inspections and audits by regulatory authorities and customers. The company may be subject to regulatory action which may damage its reputation, leading to an adverse effect on the company's business, results of operations, financial condition and cash flows.

Majority of its key raw material purchases, being APIs, excipients and intermediates, are sourced from a diversified supplier base, and the company does not enter into is not any long-term contractual agreements with them. Any reduction of supplies or discontinuation of supplies from its top suppliers could have a material adverse effect on the company's business, financial condition, results of operations and cash flows. Any fluctuation in prices of its raw materials may have a material adverse effect on the company's business, results of operations, prospects and financial condition.

The company's success depends on its ability to successfully develop and commercialize new products in a timely manner. Any failures to do so could adversely affect the company's business, results of operations and financial condition.

The company's business is dependent on the sale of products to a limited number of customers for a significant portion of its revenues. The loss of one or more such customers or the deterioration of their financial condition or prospects could adversely affect its business, results of operations and financial condition.

The company's international business exposes us to complex management, legal, tax and economic risks, which could adversely affect its business, results of operations and financial condition.

There are outstanding legal proceedings involving the Company, Promoters, some of its Directors and, the company's Material Subsidiary.

The company plans to expand and/or upgrade its Manufacturing Facilities from the Net Proceeds of the Fresh Issue and will be required to briefly stop operations in Unit I and II till such plans are completed. The company has estimated a period of 6 months for this disruption before both these units can resume operations. The company is also dependent on third-party contractors and specialist agencies who will be executing the proposed expansion and/or upgradation plans.

The Indian pharmaceutical market is subject to extensive regulation and its failures to comply with the existing and future regulatory requirements in the pharmaceutical market could adversely affect the company's business, results of operations and financial condition.